Active	Status	Sponsor type	Region	Phase	Filter
5 Active 2 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Berkovich, Regina R
NCT04048577: A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab	Recruiting	4	10	US	Dosing Interruption of Natalizumab, Dosing Interruption of Tysabri	Berkovich, Regina MD, PhD Inc., Biogen, Cedars-Sinai Medical Center	Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting	11/21	12/21
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)	Recruiting	3	800	Europe, Canada, Japan, US, RoW	Remibrutinib, LOU064, Teriflunomide	Novartis Pharmaceuticals, Novartis Pharma AG	Relapsing Multiple Sclerosis	04/26	10/30
NCT06564311: A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)	Recruiting	2	93	Europe, US, RoW	Obexelimab, Placebo	Zenas BioPharma (USA), LLC	Relapsing Multiple Sclerosis	08/25	02/26
NCT04746976: Study of Diroximel Fumarate in the Real-World Setting	Terminated	N/A	75	US	Diroximel Fumarate, VUMERITY, BIIB098	Biogen	Relapsing Forms of MS	04/23	04/23
MASTER-2, NCT03933202: A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS	Active, not recruiting	N/A	295	US	Cladribine Tablets	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Multiple Sclerosis	05/25	05/25